Mitigating the Impact on Site Monitoring Efforts Due to Covid-19 KING OF PRUSSIA, PA, US – Mar 18, 2020 – CluePoints, the premier provider of Risk-Based Trial Execution (RBx) and Data Quality Oversight Software for clinical trials, today announced that it...
Ergomed’s PrimeVigilance Announces Provision of Clinical Safety Services for COVID-19 Clinical Trial Program Guildford, UK – 30 March 2020: Ergomed plc (ERGO.L) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services...
The COVID-19 pandemic continues to dominate the news and is likely to for quite some time. The biopharma industry is doing what it can to test and repurpose therapies, develop diagnostics and respond to the crisis. Also, although some clinical trials are being slowed...
Farxiga is the first SGLT2 inhibitor to show meaningful benefit in patients with chronic kidney disease in a trial including both type-2 diabetics and non-diabetics The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III...
Crucial life-saving initiative led by Dr. Steven Quay for clinical trials on the safety and efficacy of a combination of FDA-approved drugs (nebulized Heparin-N-acetylcysteine in COVID-19 Patients by Evaluation of pulmonary function (HOPE)) SEATTLE, March 30, 2020...
Email
Text